|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
EP0446450B1
(en)
|
1990-02-09 |
1995-03-29 |
Thomas Jefferson University |
Device for collecting and processing fat tissue to produce endothelial cell product
|
|
GB2285446B
(en)
|
1994-01-03 |
1999-07-28 |
Genentech Inc |
Thrombopoietin
|
|
US5498599A
(en)
|
1994-01-21 |
1996-03-12 |
Amgen Inc. |
Methods for stimulating platelet production
|
|
EP1867720A3
(en)
|
1994-12-02 |
2008-01-09 |
Schering Corporation |
Purified genes encoding mammalian cell surface antigens; proteins and antibodies
|
|
WO1999032646A1
(en)
|
1997-12-22 |
1999-07-01 |
Oxford Biomedica (Uk) Limited |
Equine infectious anaemia virus (eiav) based
|
|
WO1999023199A1
(en)
*
|
1997-10-31 |
1999-05-14 |
Baxter International Inc. |
Closed system for processing primary tissue
|
|
EP2316490A3
(en)
|
2000-10-31 |
2012-02-01 |
PR Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
CA2469370C
(en)
*
|
2001-12-07 |
2014-07-08 |
Macropore Biosurgery, Inc. |
Adipose-derived cell processing unit
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
TW200823237A
(en)
|
2006-08-28 |
2008-06-01 |
Nuvelo Inc |
Antibodies to NTB-A
|
|
ECSP077628A
(es)
|
2007-05-03 |
2008-12-30 |
Smithkline Beechman Corp |
Nueva composición farmacéutica
|
|
EP2192905A4
(en)
|
2007-08-29 |
2010-11-10 |
Adam Lubin |
METHOD FOR SELECTIVE THERAPY OF DISEASE
|
|
EP2424463B1
(en)
*
|
2009-05-01 |
2016-12-28 |
Bimini Technologies LLC |
Systems, methods and compositions for optimizing tissue and cell enriched grafts
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
WO2011072088A2
(en)
|
2009-12-08 |
2011-06-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
JP2014509841A
(ja)
|
2011-01-18 |
2014-04-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌を治療するための組成物および方法
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
AU2012335746B2
(en)
|
2011-11-08 |
2017-04-27 |
Auxocell Laboratories, Inc. |
Systems and methods for processing cells
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
CN104379727A
(zh)
|
2012-05-18 |
2015-02-25 |
威尔逊沃夫制造公司 |
改进的用于过继细胞治疗的细胞培养方法
|
|
CN110241086A
(zh)
|
2012-06-11 |
2019-09-17 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
US20140047572A1
(en)
|
2012-08-13 |
2014-02-13 |
University Of Rochester |
Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
MX2015007446A
(es)
|
2012-12-12 |
2015-12-07 |
Vasculox Inc |
Anticuerpos terapeuticos para cd47.
|
|
WO2014133567A1
(en)
|
2013-03-01 |
2014-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
JP6257655B2
(ja)
|
2013-03-01 |
2018-01-10 |
アメリカ合衆国 |
末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
|
|
AU2013205148B2
(en)
|
2013-03-14 |
2014-10-30 |
AVITA Medical Americas, LLC |
Systems and methods for tissue processing and preparation of cell suspension therefrom
|
|
CN105452448B
(zh)
|
2013-07-15 |
2020-07-28 |
美国卫生和人力服务部 |
制备抗人乳头瘤病毒抗原的t细胞的方法
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
KR20240164967A
(ko)
|
2014-02-04 |
2024-11-21 |
카이트 파마 인코포레이티드 |
B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
|
|
EP3104866A4
(en)
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
|
US20160361476A1
(en)
|
2014-02-28 |
2016-12-15 |
Bdbc Sciences Corp. |
System for tissue manipulation
|
|
PT3149031T
(pt)
|
2014-05-29 |
2020-03-25 |
Us Health |
Receptores de células t anti-e7 do papilomavírus humano 16
|
|
UA123821C2
(uk)
|
2014-06-11 |
2021-06-09 |
Полібіосепт Гмбх |
Композиція для експансії лімфоцитів in vitro
|
|
EP4270006A3
(en)
|
2014-06-13 |
2024-01-10 |
Immudex ApS |
General detection and isolation of specific cells by binding of labeled molecules
|
|
MX381241B
(es)
|
2015-04-27 |
2025-03-12 |
Cancer Research Tech Ltd |
Composición de células t para usarse en el tratamiento del cáncer.
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
WO2017008019A1
(en)
|
2015-07-08 |
2017-01-12 |
The Johns Hopkins University |
Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
SG10201913868XA
(en)
|
2015-09-15 |
2020-03-30 |
The United States Of America As Represented By The Secretary |
T cell receptors recognizing hla-cw8 restricted mutated kras
|
|
US9650441B2
(en)
|
2015-09-21 |
2017-05-16 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
|
IL292504B2
(en)
|
2015-10-20 |
2024-01-01 |
Kite Pharma Inc |
-methods of preparing t cells for t cell therapy
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
WO2017179015A1
(en)
|
2016-04-15 |
2017-10-19 |
Glaxosmithkline Intellectual Property Development Limited |
Compositions for the treatment of cancer
|
|
CR20200608A
(es)
|
2016-04-21 |
2021-01-20 |
Immatics Biotechnologies Gmbh |
INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
US11141434B2
(en)
|
2016-07-07 |
2021-10-12 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
|
|
WO2018014039A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
|
SG11201900654QA
(en)
|
2016-08-02 |
2019-02-27 |
Us Health |
Anti-kras-g12d t cell receptors
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US20190262400A1
(en)
|
2016-10-31 |
2019-08-29 |
H. Lee Moffitt Cancer Center And Research Institure, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
|
TWI826360B
(zh)
|
2016-11-17 |
2023-12-21 |
美商艾歐凡斯生物治療公司 |
殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
EP3602053B1
(en)
|
2017-03-31 |
2023-06-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of isolating neoantigen-specific t cell receptor sequences
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
AU2018335274B2
(en)
|
2017-09-20 |
2025-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA class II–restricted T cell receptors against mutated RAS
|
|
JP7391015B2
(ja)
|
2017-09-29 |
2023-12-04 |
アメリカ合衆国 |
P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法
|
|
JP7557367B2
(ja)
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
GB201801067D0
(en)
|
2018-01-23 |
2018-03-07 |
Price Nicola Kaye |
Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
|
|
KR20200119840A
(ko)
*
|
2018-02-09 |
2020-10-20 |
이매틱스 유에스 인코포레이티드 |
T 세포의 제조 방법
|
|
ES3052818T3
(en)
|
2018-02-09 |
2026-01-14 |
Us Health |
Tethered interleukin-15 and interleukin-21
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
EA202092319A1
(ru)
|
2018-03-29 |
2021-03-04 |
Айовэнс Байотерапьютикс, Инк. |
Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
GB201810181D0
(en)
|
2018-06-21 |
2018-08-08 |
Immetacyte Ltd |
Cells expressing chimeric recominant growth factor receptors
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
US12453697B2
(en)
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
IL282775B1
(en)
|
2018-11-05 |
2026-05-01 |
Iovance Biotherapeutics Inc |
Selection of enhanced carrier-reactive T cells
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
CN118931967A
(zh)
|
2018-12-07 |
2024-11-12 |
亘喜生物科技(上海)有限公司 |
用于免疫疗法的组合物和方法
|
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
US20220112557A1
(en)
|
2019-01-10 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
|
GB201900858D0
(en)
|
2019-01-22 |
2019-03-13 |
Price Nicola Kaye |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
CA3128778A1
(en)
|
2019-03-01 |
2020-09-10 |
Asymptote Ltd |
Closed tissue disaggregation and cryopreservation
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
GB201910605D0
(en)
|
2019-07-24 |
2019-09-04 |
Immetacyte Ltd |
Tumour infltracting lymphocyte therapy amd uses thereo
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
FR3105367A1
(fr)
|
2019-12-20 |
2021-06-25 |
Valeo Systemes Thermiques |
Module de dispositif de ventilation pour module de refroidissement de véhicule automobile, dispositif de ventilation comportant un tel module et module de refroidissement pour véhicule automobile comprenant un tel dispositif de ventilation
|
|
JP2023507432A
(ja)
|
2019-12-20 |
2023-02-22 |
インスティル バイオ (ユーケイ) リミテッド |
腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
|
|
EP4139440B1
(en)
|
2020-04-22 |
2026-08-19 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4146793A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
WO2021226061A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CN116348485A
(zh)
|
2020-07-17 |
2023-06-27 |
英研生物(英国)有限公司 |
提供用于过继性细胞疗法的靶向共刺激的受体
|
|
WO2022016114A1
(en)
|
2020-07-17 |
2022-01-20 |
Instill Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022087324A1
(en)
|
2020-10-22 |
2022-04-28 |
Iovance Biotherapeutics, Inc. |
Cell culture system and methods of using the same
|
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
EP4263807A2
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Processing of tumor infiltrating lymphocytes
|
|
CA3205464A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Processing of tumor infiltrating lymphocytes
|
|
JP2024501845A
(ja)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|